Observational Studies of Statins in Heart Failure with Preserved Systolic Function

Heart Failure Clinics

Volumn 4, Issue 2, 2008, Pages 209-216

  Fukuta, Hidekatsu ^a   Little, William C ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FLUINDOSTATIN; FUROSEMIDE; GLYCERYL TRINITRATE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIASTOLIC HEART FAILURE; DRUG EFFECT; DRUG INDICATION; ECHOCARDIOGRAPHY; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; LUNG EDEMA; MORTALITY; OBSERVATIONAL STUDY; REVIEW; STRESS ECHOCARDIOGRAPHY; SURVIVAL; SYSTOLE; THORAX RADIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; DIASTOLE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SYSTOLE;

EID: 42349095833     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.01.005     Document Type: Review

References (74)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
3. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
4. Levine G.N., Keaney Jr. J.F., and Vita J.A. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 332 (1995) 512-521
5. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
6. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
7. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
8. Horwich T.B., Hamilton M.A., Maclellan W.R., et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
9. Rauchhaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
10. Afsarmanesh N., Horwich T.B., and Fonarow G.C. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 152 (2006) 1077-1083
11. Horwich T.B., Maclellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
12. Mozaffarian D., Nye R., and Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
13. Sola S., Mir M.Q., Rajagopalan S., et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 11 (2005) 607-612
14. Anker S.D., Clark A.L., Winkler R., et al. Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients. Int J Cardiol 112 (2006) 234-242
15. Krum H., Latini R., Maggioni A.P., et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 119 (2007) 48-53
16. Owan T.E., and Redfield M.M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47 (2005) 320-332
17. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
18. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
19. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 296 (2006) 2209-2216
20. Fukuta H., Sane D.C., Brucks S., et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
21. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
22. Roik M., Starczewska M.H., Stawicki S., et al. Impact of statin therapy on survival in patients with diastolic heart failure. Eur Heart J 27 Suppl 1 (2006) 23
23. Folkeringa R.J., Van Kraaij D.J., Tieleman R.G., et al. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 12 (2006) 134-138
24. Go A.S., Lee W.Y., Yang J., et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
25. Ray J.G., Gong Y., Sykora K., et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 (2005) 62-67
26. Foody J.M., Shah R., Galusha D., et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
27. Senni M., Tribouilloy C.M., Rodeheffer R.J., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98 (1998) 2282-2289
28. Vasan R.S., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (1999) 1948-1955
29. Ahmed A., Zile M.R., Rich M.W., et al. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol 99 (2007) 460-464
30. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
31. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
32. Nishikawa H., Miura S., Zhang B., et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 68 (2004) 121-125
33. Patel R., Nagueh S.F., Tsybouleva N., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 (2001) 317-324
34. Indolfi C., Di L.E., Perrino C., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 106 (2002) 2118-2124
35. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105 (2002) 1503-1508
36. Aurigemma G.P., and Gaasch W.H. Clinical practice: diastolic heart failure. N Engl J Med 351 (2004) 1097-1105
37. Redfield M.M. Understanding diastolic heart failure. N Engl J Med 350 (2004) 1930-1931
38. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 11 (2002) 489-496
39. Glorioso N., Troffa C., Filigheddu F., et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 34 (1999) 1281-1286
40. Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 39 (2002) 1020-1025
41. Smilde T.J., van den Berkmortel F.W., Wollersheim H., et al. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 30 (2000) 473-480
42. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-III43
43. Wilkinson I.B., Qasem A., McEniery C.M., et al. Nitric oxide regulates local arterial distensibility in vivo. Circulation 105 (2002) 213-217
44. Landmesser U., Bahlmann F., Mueller M., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
45. Farrar D.J., Green H.D., Wagner W.D., et al. Reduction in pulse wave velocity and improvement of aortic distensibility accompanying regression of atherosclerosis in the rhesus monkey. Circ Res 47 (1980) 425-432
46. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 (2002) 2884-2887
47. O'Rourke M.F. Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance. J Am Coll Cardiol 38 (2001) 803-805
48. Kass D.A., Bronzwaer J.G., and Paulus W.J. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 94 (2004) 1533-1542
49. Bauersachs J., Galuppo P., Fraccarollo D., et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
50. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
51. Zaca V., Rastogi S., Imai M., et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 50 (2007) 551-557
52. Saka M., Obata K., Ichihara S., et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 47 (2006) 770-779
53. Ichihara S., Noda A., Nagata K., et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 69 (2006) 726-735
54. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
55. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
56. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After Cardiac Surgery) study. Circulation 114 (2006) 1455-1461
57. Humphries K.H., Lee M., Sheldon R., et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 154 (2007) 908-913
58. Mitchell L.B., Powell J.L., Gillis A.M., et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
59. Vyas A.K., Guo H., Moss A.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
60. Goldberger J.J., Subacius H., Schaechter A., et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1228-1233
61. Dickinson M.G., Ip J.H., Olshansky B., et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 153 (2007) 573-578
62. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
63. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
64. Givertz M.M., and Colucci W.S. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 352 Suppl 1 (1998) SI34-SI38
65. Olsson L.G., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program. J Am Coll Cardiol 47 (2006) 1997-2004
66. Solomon S.D., Wang D., Finn P., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Circulation 110 (2004) 2180-2183
67. Solomon S.D., Anavekar N., Skali H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005) 3738-3744
68. Rauchhaus M., Coats A.J., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 (2000) 930-933
69. Zile M.R. Treating diastolic heart failure with statins: phat chance for pleiotropic benefits. Circulation 112 (2005) 300-303
70. Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
71. Tavazzi L., Tognoni G., Franzosi M.G., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
72. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
73. Masoudi F.A. Statins for ischemic systolic heart failure. N Engl J Med 357 (2007) 2301-2304
74. Senni M., and Redfield M.M. Heart failure with preserved systolic function. A different natural history?. J Am Coll Cardiol 38 (2001) 1277-1282